ライフサイエンス研究メディア

バイオマーケットjpはバイオ・ライフサイエンス研究に役立つ情報を発信するWebメディアです

Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients


Posted: 2021-09-29 19:00:00
The prognosis of the coronavirus disease 2019 (COVID-19) patients is variable and depends on several factors. Current data about the impact of chronic obstructive pulmonary disease (COPD) and smoking on the clinical course of COVID-19 are still controversial. This study evaluated the prevalence and the prognosis of COPD patients and smokers in a cohort of 521 patients admitted to four intermediate Respiratory Intensive Care Units (Puglia, Italy) with respiratory failure due to COVID-19 pneumonia. The prevalence of COPD and current smokers was 14% and 13%, respectively. COPD patients had a higher 30-day all-cause mortality than non-COPD patients. Former smokers compared to never smokers and current smokers had higher 30-day all-cause mortality. COPD patients and former smokers had more comorbidities. This study described the prevalence and the outcomes of COPD patients and smokers in a homogenous cohort of COVID-19 patients. The study showed that the prevalence of COPD and current smokers was not high, suggesting that they were not at increased risk of getting the infection. However, when SARS-CoV-2 infection occurred, COPD patients and former smokers were those with the highest all-cause mortality, which seemed to be mainly related to the presence of comorbidities and not to COPD and smoking itself.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
3月 31, 2021 バイオアソシエイツ

宿主遺伝子の発現を阻害するウイルスタンパク質(Nsp1)を標的としたCOVID-19治療アプローチの可能性

Nsp1と呼ばれるコロナウイルスタンパク質が遺伝子の活性をどのように抑制し、ウイルス複製を促進するかを特定する研究は、新しい COVID-19 治療への希望をもたらすものだ。 パンデミックが始まって以来、科学者らは、 COVID-19 の原因となるコロナウイルスであるSARS-CoV-2を理解するために果てしなく取り組んできた。ワクチンの登場にもかかわらず、ウイルスはまだ蔓延しており、代替療法を開発する必要がある。…

ゲスト 886人 と メンバー 7人 がオンラインです